rezdiffra
(Resmetirom)Madrigal Pharmaceuticals, Inc.
Usage: REZDIFFRA is indicated for adults with noncirrhotic nonalcoholic steatohepatitis (NASH) and moderate to advanced liver fibrosis (F2 to F3), when used alongside diet and exercise. Approval is based on early evidence of efficacy, with continued approval dependent on further confirmation of clinical benefits. Avoid in decompensated cirrhosis.